Small peptide analogue of SDF-1alpha supports survival of cord blood CD34+ cells in synergy with other cytokines and enhances their ex vivo expansion and engraftment into nonobese diabetic/severe combined immunodeficient mice

The SDF-1/CXCR4 axis has been implicated in the chemotaxis, homing, mobilization, and expansion of hematopoietic stem and progenitor cells. We studied the effects of a SDF-1 peptide analogue CTCE-0214 on the survival of cord blood CD34+ cells in culture, expansion, and engraftment of expanded cells...

Full description

Saved in:
Bibliographic Details
Published in:Stem cells (Dayton, Ohio) Ohio), 2006-01, Vol.24 (1), p.55
Main Authors: Li, Karen, Chuen, Carmen Ka Yee, Lee, Shuk Man, Law, Ping, Fok, Tai Fai, Ng, Pak Cheung, Li, Chi Kong, Wong, Donald, Merzouk, Ahmed, Salari, Hassan, Gu, Goldie Jia-Shi, Yuen, Patrick Man Pan
Format: Article
Language:English
Subjects:
Animals
Antigens, CD34 - metabolism
Cell Survival - drug effects
Chemokine CXCL12
Chemokines, CXC - physiology
Cytokines - pharmacology
Dose-Response Relationship, Drug
Drug Synergism
Fetal Blood - cytology
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells
Membrane Proteins - pharmacology
Mice
Mice, SCID
Receptors, CXCR4 - metabolism
Stem Cell Factor - pharmacology
Thrombopoietin - pharmacology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The SDF-1/CXCR4 axis has been implicated in the chemotaxis, homing, mobilization, and expansion of hematopoietic stem and progenitor cells. We studied the effects of a SDF-1 peptide analogue CTCE-0214 on the survival of cord blood CD34+ cells in culture, expansion, and engraftment of expanded cells in the nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model. Our results demonstrated that CTCE-0214 synergized with thrombopoietin (TPO), stem cell factor (SCF), or flt-3 ligand (FL) on the survival of stem and progenitor cells in culture. Adding CTCE-0214 at a low concentration (0.01 ng/ml) for 4 days together with TPO, SCF, and FL significantly enhanced ex vivo expansion of CD34+ cells to subsets of primitive (CD34+CD38- cells, colony-forming unit-mixed [CFU-GEMMs]), erythroid (CFU-Es), myeloid (CFU-GMs), and megakaryocytic (CD61+CD41+ cells, CFU-MKs) progenitors, as well as their multilineage engraftment in NOD/SCID mice. Interestingly, the short exposure of expanded cells to CTCE-0214 (100 and 500 ng/ml) for 4 hours did not increase the quantity of progenitor cells but enhanced their engraftment capacity. The proportion of CD34+ cells expressing surface CXCR4 was decreased, but the overall number of this population increased upon expansion. The small peptide analogue of SDF-1 could be developed for ex vivo expansion and improving engraftment of cord blood transplantation.
ISSN:1066-5099
1549-4918